| Name | Title | Contact Details |
|---|
Child Health Corporation of America (CHCA) is a legacy business alliance of children's hospitals. CHCA children's hospitals represented more than 20,000 physicians, 100,000 employees, $14 billion in revenue and $1.8 billion in overall medical, surgical and pharmaceutical products. CHCA's former Owner Hospitals are North America's leading children's hospitals and are widely known for their excellence in caring for America's children. In 2011, CHCA, the National Association of Children's Hospitals and Related Institutions (NACHRI) and its public policy affiliate National Association of Children's Hospitals (N.A.C.H.) merged to pool our strengths and talents, creating a new organization, the Children’s Hospital Association. We share members, a common board of trustees and new President and CEO Mark Wietecha. As one Association, we will continue to be champions for children’s health.
Health Dialog is a total population healthcare services provider that offers risk-bearing entities (health plans, employers, and providers) an integrated suite of services driven by powerful analytics. These services include member engagement programs, multi-channel health coaching, medication adherence support, and shared decision making tools. We are part of the Rite Aid family. Through client partnerships and customized engagements, our dedicated team of healthcare professionals helps clients improve quality of care and reduce healthcare costs while empowering individuals to make informed health and wellness decisions.
Olean General Hospital/Bradford Regional Medical Center is a healthcare provider offering primary and specialty care to residents in southwestern New York state and northwestern Pennsylvania.
Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.
MedServe is a Bellaire, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.